Brief: ADC Therapeutics Announces Voluntary Pause Of Enrollment In Phase 2 Lotis-9 Clinical Trial Of Zynlonta And Rituximab

ADC Therapeutics SA

11/07/2023 12:47

July 11 (Reuters) - ADC Therapeutics SA  ADCT.N :
    * ADC THERAPEUTICS ANNOUNCES VOLUNTARY PAUSE OF ENROLLMENT
IN THE
PHASE 2 LOTIS-9 CLINICAL TRIAL OF ZYNLONTA® (LONCASTUXIMAB
TESIRINE-LPYL) AND RITUXIMAB IN UNFIT OR FRAIL PREVIOUSLY
UNTREATED DLBCL PATIENTS
    * ADC THERAPEUTICS- PAUSE AFTER REVIEW OF DATA OF 40
PATIENTS
ENROLLED IN TRIAL WHICH SIGNALED POTENTIALLY EXCESSIVE
RESPIRATORY-RELATED EVENTS
    * ADC THERAPEUTICS - RESPIRATORY-RELATED EMERGENT AES
INCLUDED
SEVEN GRADE 5 FATAL EVENTS & FIVE GRADE 3 OR GRADE 4
RESPIRATORY-RELATED TEAES
    * ADC THERAPEUTICS SA -  AS PER INVESTIGATOR ASSESSMENT,
ELEVEN OF
TWELVE EVENTS WERE INDIVIDUALLY ASSESSED AS UNLIKELY OR
UNRELATED TO STUDY DRUG
    * ADC THERAPEUTICS SA - FOUR OUT OF FIVE GRADE 3 OR GRADE 4
EVENTS
HAVE SINCE RESOLVED AND PATIENTS HAVE COMPLETED TREATMENT PER
PROTOCOL
    * ADC THERAPEUTICS SA - CAUSE OF THESE EVENTS REMAINS UNDER
FURTHER INVESTIGATION
    * ADC THERAPEUTICS SA - COMPANY'S DECISION TO PAUSE
ENROLLMENT
ENABLES TIME TO EVALUATE DATA AROUND TEAES AND DETERMINE NEXT
STEPS
    * ADC THERAPEUTICS SA - DOES NOT EXPECT TO REPORT ADDITIONAL
DATA
FROM TRIAL BY END OF YEAR

Source text for Eikon:  ID:nGNX6V03Tp 
Further company coverage:  ADCT.N 

 ((reuters.briefs@thomsonreuters.com;))